Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Trevi Therapeutics ( (TRVI) ).
Trevi Therapeutics, a biopharmaceutical company focused on chronic cough treatments, has announced key executive changes with James Cassella joining as Chief Development Officer and David Clark stepping down as Chief Medical Officer but continuing as a consultant. The company’s investigational therapy, Haduvio, aims to address unmet medical needs in chronic cough conditions and is advancing towards pivotal development and potential regulatory submission. Cassella’s extensive experience in CNS drug development is expected to significantly contribute to Haduvio’s progress.
For a thorough assessment of TRVI stock, go to TipRanks’ Stock Analysis page.